ECSP22052564A - Tetrahidrofuranos sustituidos como moduladores de canales de sodio - Google Patents

Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Info

Publication number
ECSP22052564A
ECSP22052564A ECSENADI202252564A ECDI202252564A ECSP22052564A EC SP22052564 A ECSP22052564 A EC SP22052564A EC SENADI202252564 A ECSENADI202252564 A EC SENADI202252564A EC DI202252564 A ECDI202252564 A EC DI202252564A EC SP22052564 A ECSP22052564 A EC SP22052564A
Authority
EC
Ecuador
Prior art keywords
sodium channel
tetrahydrofuranes
substituted
channel modulators
compounds
Prior art date
Application number
ECSENADI202252564A
Other languages
English (en)
Inventor
Ewa Chudyk
Steven Durrant
Christopher Wray
Meireles Lidio Carvalho
Ronald Knegtel
Nadia Ahmad
Robert Pullin
Timothy Neubert
Ruah Sara S Hadida
Yvonne Schmidt
Elizabeth Beck
Anisa Virani
Joseph Pontillo
Dean Stamos
Sarah Skerratt
Joanne Pinder
David Shaw
Jardi Gorka Etxebarria
Stephen Thomson
Dennis Hurley
Bhairavi Galan
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73854989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22052564(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP22052564A publication Critical patent/ECSP22052564A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Details Of Television Scanning (AREA)
  • Amplitude Modulation (AREA)
  • Amplifiers (AREA)

Abstract

Se proporcionan compuestos y sus sales farmac?uticamente aceptables, de utilidad como inhibidores de canales de sodio. Tambi?n se proporcionan composiciones farmac?uticas que comprenden los compuestos o sales farmac?uticamente aceptables y m?todos de uso de los compuestos, sales farmac?uticamente aceptables y composiciones farmac?uticas en el tratamiento de diversos trastornos, incluyendo el dolor.
ECSENADI202252564A 2019-12-06 2022-07-05 Tetrahidrofuranos sustituidos como moduladores de canales de sodio ECSP22052564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944869P 2019-12-06 2019-12-06
PCT/US2020/063290 WO2021113627A1 (en) 2019-12-06 2020-12-04 Substituted tetrahydrofurans as modulators of sodium channels

Publications (1)

Publication Number Publication Date
ECSP22052564A true ECSP22052564A (es) 2022-08-31

Family

ID=73854989

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202252564A ECSP22052564A (es) 2019-12-06 2022-07-05 Tetrahidrofuranos sustituidos como moduladores de canales de sodio

Country Status (36)

Country Link
US (4) US11834441B2 (es)
EP (2) EP4506001A3 (es)
JP (2) JP7664925B2 (es)
KR (1) KR20220124176A (es)
CN (1) CN114945566B (es)
AR (1) AR120680A1 (es)
AU (1) AU2020397059A1 (es)
BR (1) BR112022010924A2 (es)
CA (1) CA3164134A1 (es)
CL (1) CL2022001489A1 (es)
CO (1) CO2022008969A2 (es)
CR (1) CR20220316A (es)
DK (1) DK4069691T3 (es)
DO (2) DOP2022000115A (es)
EC (1) ECSP22052564A (es)
ES (1) ES2998396T3 (es)
FI (1) FI4069691T3 (es)
HR (1) HRP20241695T1 (es)
HU (1) HUE069128T2 (es)
IL (1) IL293592A (es)
JO (1) JOP20220130B1 (es)
LT (1) LT4069691T (es)
MA (1) MA57825B1 (es)
MD (1) MD4069691T2 (es)
MX (1) MX2022006865A (es)
PE (1) PE20230300A1 (es)
PH (1) PH12022551379A1 (es)
PL (1) PL4069691T3 (es)
PT (1) PT4069691T (es)
RS (1) RS66307B1 (es)
SI (1) SI4069691T1 (es)
SM (1) SMT202400488T1 (es)
TW (1) TWI891687B (es)
UA (1) UA130303C2 (es)
UY (1) UY38979A (es)
WO (1) WO2021113627A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
EP3999510A1 (en) 2019-07-16 2022-05-25 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
JP2024522290A (ja) * 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの置換テトラヒドロフラン調節因子の合成のためのプロセス
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
CA3221939A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
US11999699B2 (en) 2021-06-15 2024-06-04 Grünenthal GmbH Substituted pyrazole amides
TW202322794A (zh) * 2021-09-24 2023-06-16 加拿大商再諾製藥公司 做為鈉通道活化劑之吡啶基衍生物
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CR20240512A (es) 2022-04-25 2025-03-03 Siteone Therapeutics Inc Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor
US20260055088A1 (en) * 2022-08-24 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heterocyclic compound, method for preparing same, and pharmaceutical use thereof
CN119731169A (zh) * 2022-08-28 2025-03-28 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024046409A1 (zh) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
EP4630405A1 (en) * 2022-12-06 2025-10-15 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
AR131345A1 (es) 2022-12-14 2025-03-12 Gruenenthal Gmbh SULFOXIMINAS COMO INHIBIDORES DE NaV1.8
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8
CN120569377A (zh) * 2023-01-06 2025-08-29 海思科医药集团股份有限公司 一种四氢噻吩衍生物及其在医药上的应用
WO2024188367A1 (zh) * 2023-03-10 2024-09-19 西藏海思科制药有限公司 一种四氢呋喃衍生物及其在医药上的应用
WO2024217557A1 (zh) * 2023-04-19 2024-10-24 武汉人福创新药物研发中心有限公司 取代的四氢呋喃作为Nav1.8抑制剂
WO2024217528A1 (zh) * 2023-04-20 2024-10-24 西藏海思科制药有限公司 一种杂环化合物及其在医药上的应用
CN119371405A (zh) 2023-07-26 2025-01-28 上海闻耐医药科技有限公司 多取代吡咯烷类衍生物、其制备方法及用途
WO2025067219A1 (zh) * 2023-09-25 2025-04-03 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
TW202535352A (zh) * 2023-11-02 2025-09-16 大陸商陽光安津（南京）生物醫藥科技有限公司 化合物、組合物及其方法
WO2025108234A1 (zh) * 2023-11-20 2025-05-30 四川科伦药物研究院有限公司 化合物、其制备方法及用途
WO2025113633A1 (zh) * 2023-12-01 2025-06-05 南京清普生物科技有限公司 一种新的钠通道调节剂
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
WO2025131099A1 (zh) * 2023-12-21 2025-06-26 武汉熙瑞医药科技有限公司 一种含苯环的多环化合物、其药物组合物及其应用
WO2025131100A1 (zh) * 2023-12-21 2025-06-26 武汉熙瑞医药科技有限公司 一种含苯环的多环化合物、其药物组合物及其应用
CN120192306A (zh) * 2023-12-21 2025-06-24 武汉熙瑞医药科技有限公司 一种含苯环的多环化合物、其药物组合物及其应用
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025162194A1 (zh) * 2024-01-31 2025-08-07 上海汇伦医药股份有限公司 钠通道调节剂新化合物及其应用
TW202545937A (zh) * 2024-02-01 2025-12-01 大陸商海思科醫藥集團股份有限公司 含硫雜環衍生物及其在醫藥上的應用
WO2025168043A1 (zh) * 2024-02-08 2025-08-14 上海枢境生物科技有限公司 并环类衍生物、制备方法及其用途
CN120040429A (zh) * 2024-02-23 2025-05-27 山东盛迪医药有限公司 一种取代四氢呋喃衍生物的结晶形式及其用途
CN120058685A (zh) * 2024-02-23 2025-05-30 山东盛迪医药有限公司 一种取代四氢呋喃化合物的结晶形式及其制备方法
CN120040430A (zh) * 2024-02-23 2025-05-27 山东盛迪医药有限公司 一种取代四氢呋喃衍生物的可药用盐、其结晶形式及用途
CN120058686A (zh) * 2024-02-23 2025-05-30 山东盛迪医药有限公司 一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途
WO2025223433A1 (zh) * 2024-04-22 2025-10-30 晶新医药研发（上海）有限公司 一种五元杂环类化合物、药物组合物及其应用
CN118388466A (zh) * 2024-04-23 2024-07-26 安润医药科技（苏州）有限公司 作钠通道调节剂的酰胺衍生物及其用途
CN121045232A (zh) * 2024-05-31 2025-12-02 熙源安健医药(北京)有限公司 杂环类衍生物及其制备方法和用途
WO2025252109A1 (zh) * 2024-06-04 2025-12-11 成都苑东生物制药股份有限公司 一种取代四氢呋喃类衍生物、其制备方法及用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
CN118772124A (zh) * 2024-07-01 2024-10-15 山东福长药业有限公司 一种Suzetrigine的制备方法
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain
CN121591707A (zh) * 2024-08-15 2026-03-03 思路迪生物医药(上海)有限公司 选择性钠通道调节剂及其制备和应用
WO2026037326A1 (zh) * 2024-08-16 2026-02-19 四川科伦药物研究院有限公司 吡啶酰胺类化合物的盐和晶型及其制备方法
CN119613390B (zh) * 2024-11-11 2025-10-28 广州楷石医药有限公司 氘代四氢呋喃类NaV1.8抑制剂及其用途
CN119143737B (zh) * 2024-11-18 2025-07-18 嘉兴安帝康生物科技有限公司 四氢呋喃甲酰胺类钠通道调节剂及其在医药上的应用
CN119859142A (zh) * 2024-11-28 2025-04-22 四川科伦药物研究院有限公司 杂环化合物的晶型及其药物组合物
CN119285621B (zh) * 2024-12-13 2025-07-18 嘉兴安帝康生物科技有限公司 作为钠通道调节剂的四氢呋喃甲酰胺类化合物及其在医药上的应用

Family Cites Families (413)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844732A (en) 1985-10-24 1989-07-04 Daicel Chemical Industries Ltd. Pyridine-3-carboxamide derivatives
JPH075554B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ５−ブロモピリドン−３−カルボキサミド化合物の製法
JPH075555B2 (ja) 1986-02-25 1995-01-25 ダイセル化学工業株式会社 ピリドン−３−カルボキサミドの製法
IE902465A1 (en) 1989-07-07 1991-02-13 Schering Corp Pharmaceutically active compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
JPH05107574A (ja) 1991-03-12 1993-04-30 Mitsui Petrochem Ind Ltd 有機非線形光学材料
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
IT1254134B (it) 1992-01-16 1995-09-08 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso chimicamente modificati.
SG65570A1 (en) 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
CA2144763A1 (en) 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB2300856A (en) 1995-05-16 1996-11-20 Pfizer Ltd Beta-lactam preparation
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
CN1268140A (zh) 1996-10-16 2000-09-27 Icn药品公司 单环l－核苷、类似物及其应用
EP0935463B1 (en) 1996-10-31 2004-01-21 Harbor Branch Oceanographic Institution, Inc. Use of anti-neurogenic inflammatory compounds and compositions
JPH10213820A (ja) 1997-01-31 1998-08-11 Canon Inc 液晶素子及び液晶装置
US5942508A (en) 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
CA2307613A1 (en) 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
CN1332722A (zh) 1998-09-30 2002-01-23 宝洁公司 2－取代的酮酰胺
AU1230100A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2001012183A1 (en) 1999-08-16 2001-02-22 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
CZ20021355A3 (cs) 1999-10-29 2002-11-13 Pfizer Products Inc. Deriváty hygromycinu
ATE318809T1 (de) 1999-11-05 2006-03-15 Sod Conseils Rech Applic Heterocyclische verbindungen und ihre verwendung als medikamente
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
JP2004500389A (ja) 2000-03-09 2004-01-08 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒメディエーターの治療での使用
EP1303757B1 (en) 2000-07-10 2006-10-11 Vertex Pharmaceuticals (San Diego) LLC Ion channel assay methods
CA2419966A1 (en) 2000-09-06 2002-03-14 Neurogen Corporation Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
WO2002060905A2 (en) 2000-10-24 2002-08-08 Glaxo Group Ltd Process for preparing intermediates of hiv protease inhibitors
MXPA03003829A (es) 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1353913A2 (en) 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic heterocyclic compounds
MXPA03007935A (es) 2001-03-05 2003-12-04 Du Pont Agentes de diamina heterociclica de control de animales invertebrados daninos.
MXPA03009000A (es) 2001-04-13 2004-02-12 Boehringer Ingelheim Pharma Compuestos benzo-fusionados 1,4-disustituidos.
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
WO2003070912A2 (en) 2001-06-06 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003000245A1 (en) 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
CN110894196A (zh) 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1467985A1 (en) 2002-01-22 2004-10-20 E.I. Du Pont De Nemours And Company Diamide invertebrate pest control agents
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
ES2334990T3 (es) 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
JP2005523292A (ja) 2002-02-21 2005-08-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体モジュレーター
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
AU2003237224A1 (en) * 2002-05-29 2003-12-19 Merck And Co., Inc. 1,2 diamido cycloalkyl sodium channel blockers
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004063151A2 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
SG2012000667A (en) 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
JP4742029B2 (ja) 2003-04-01 2011-08-10 アクティブクス バイオサイエンシズ、インコーポレイテッド アシル−リン酸及びホスホン酸プローブ並びにその合成方法並びにプロテオーム分析における使用
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ATE439837T1 (de) 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
RU2006108577A (ru) 2003-08-21 2007-09-27 Гриффит Юниверсити (Au) Новые сульфенамиды
WO2005019237A1 (en) 2003-08-21 2005-03-03 Griffith University Novel sulfenamides
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4526801B2 (ja) 2003-11-13 2010-08-18 新日鐵化学株式会社 複素環化合物の製造方法
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
CA2545192A1 (en) 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
BRPI0513717A (pt) 2004-07-23 2008-05-13 Pfizer derivados de piridina
EP1786415A4 (en) 2004-08-16 2010-01-20 Verva Pharmaceuticals Pty METABOLISM MODULATION AGENTS AND USES THEREOF
CN101068794B (zh) 2004-09-02 2012-12-19 沃泰克斯药物股份有限公司 可用作离子通道调控剂的喹唑啉
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US8461128B2 (en) 2005-04-15 2013-06-11 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
CN101175718A (zh) 2005-05-09 2008-05-07 沃泰克斯药物股份有限公司 制备联芳基脲及其类似物的方法
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
JP5112297B2 (ja) 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なキノリン誘導体
JP5388574B2 (ja) 2005-05-31 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なヘテロ環式類
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
AU2006335042A1 (en) 2005-10-21 2007-07-19 Glaxo Group Limited Compounds
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US20070203224A1 (en) 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
WO2007095187A2 (en) 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
US7480400B2 (en) 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
EP2035395A2 (en) 2006-06-27 2009-03-18 Glenmark Pharmaceuticals S.A. Novel processes for the preparation of dpp iv inhibitors
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
EP1882475A1 (en) 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
HRP20110017T1 (hr) 2006-08-08 2011-02-28 Millennium Pharmaceuticals Spojevi heteroarila korisni kao inhibitori e1 aktivirajućih enzima
JP5244596B2 (ja) 2006-08-09 2013-07-24 株式会社アイエスティー タンパク質の検出方法及びそれに用いる蛍光色素
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
CN101534831B (zh) 2006-09-11 2013-07-17 柯瑞斯公司 包含锌结合基团的取代的酪氨酸抑制剂
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0719345A2 (pt) 2006-11-27 2014-03-18 Novartis Ag Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
CA2672737A1 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
CN101674833A (zh) 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
WO2008135826A2 (en) * 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
JP2010531304A (ja) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
SG187396A1 (en) 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2009036051A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
CA2700088A1 (en) 2007-09-26 2009-04-02 Astellas Pharma Inc. Quinolone derivative
CA2700783C (en) 2007-10-08 2015-03-17 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
RU2010118481A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов
EP2227453B1 (en) 2007-10-11 2016-03-09 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118467A (ru) 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
WO2009069132A2 (en) 2007-11-29 2009-06-04 Ramot At Tel Aviv University Ltd. Novel reverse transcriptase inhibitors
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2244571A4 (en) 2008-01-17 2014-02-19 Purdue Research Foundation SMALL MOLECULAR INHIBITORS OF HIV PROTEASES
US20120108630A1 (en) 2008-02-12 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog Pathway Antagonists and Methods of Use
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
CN102046179B (zh) 2008-04-09 2015-01-14 英菲尼提制药公司 脂肪酸酰胺水解酶抑制剂
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
US8541569B2 (en) 2008-09-06 2013-09-24 Chemgenes Corporation Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA
AU2009288632B2 (en) 2008-09-06 2015-08-13 Chemgenes Corporation RNA synthesis - phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3' - end
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN102227420B (zh) 2008-09-29 2015-06-24 西特里斯药业公司 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2184273A1 (de) 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
EP2384328B1 (en) 2008-11-27 2013-02-13 Boehringer Ingelheim International GmbH 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
US20110237622A1 (en) 2008-12-10 2011-09-29 Merck Frosst Canada Ltd. Renin inhibitors
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
BRPI0924059A2 (pt) 2008-12-23 2015-07-07 Hoffmann La Roche Didro piridona amidas como moduladores de p2x7
PL2380881T3 (pl) 2008-12-26 2017-07-31 Sumitomo Dainippon Pharma Co., Ltd. Nowy bicykliczny związek heterocykliczny
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
AU2010233917B2 (en) 2009-04-02 2015-07-02 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
TWI770731B (zh) 2009-04-28 2022-07-11 美商環球展覽公司 具有甲基-d3取代之銥錯合物
CN102459273A (zh) 2009-05-07 2012-05-16 里兰斯坦福初级大学理事会 用于研究、成像以及治疗疼痛的方法和组合物
CN102459264A (zh) 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US20120189670A1 (en) 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
PH12012500734A1 (en) 2009-10-16 2012-11-26 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2569307A2 (en) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US20120010235A1 (en) 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
WO2012007836A1 (en) * 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012020725A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
BR112013008240A2 (pt) 2010-10-08 2017-12-12 Abbvie Inc compostos de furo [3-2-d] pirimidina
GB201017315D0 (en) 2010-10-13 2010-11-24 Antoxis Ltd Compound
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
FI20106119A0 (fi) 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus
GB201020076D0 (en) 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
MX2013005994A (es) 2010-11-29 2013-07-15 Pfizer Monobactamas.
KR20130129406A (ko) 2010-12-13 2013-11-28 뉴럴 패쓰웨이즈, 엘엘씨 축 길이가 조절가능한 휴대용 ｅｍｇ 자극 장치
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
WO2012097330A2 (en) 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
TWI520964B (zh) 2011-02-02 2016-02-11 維泰克斯製藥公司 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺
JP2012167027A (ja) 2011-02-10 2012-09-06 Shionogi & Co Ltd Ｎｐｙｙ５受容体拮抗作用を有する縮合ヘテロ環誘導体
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
AU2012229952A1 (en) 2011-03-15 2013-04-18 Abbvie Inc. Nuclear hormone receptor modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP5866100B2 (ja) 2011-04-13 2016-02-17 住友化学株式会社 レジスト組成物及びレジストパターンの製造方法
BR112013028983A2 (pt) 2011-05-11 2017-02-07 Sanofi Sa antagonistas mdm2 espiro-oxindol
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
WO2012170371A1 (en) 2011-06-10 2012-12-13 N30 Pharmaceuticals, Llc Compounds as s-nitrosoglutathione reductase inhibitors
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
RS56534B1 (sr) 2011-09-12 2018-02-28 Merck Patent Gmbh Novi imidazol akmini kao modulatori aktivnosti kinaza
WO2013049725A2 (en) 2011-09-30 2013-04-04 Tufts University Methods of using adenosine a1 receptor activation for treating depression
UA109220C2 (uk) 2011-10-26 2015-07-27 Пфайзер Лімітед Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用
US9403839B2 (en) 2012-01-16 2016-08-02 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
FR2985916B1 (fr) 2012-01-25 2015-12-04 Univ Bordeaux Segalen Decontamination par hydrogels d'echantillons aqueux contenant des nanoparticules
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
US9745339B2 (en) 2012-02-08 2017-08-29 Novalix Deutschland Gmbh Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV
US10934487B2 (en) 2012-02-22 2021-03-02 Merck Patent Gmbh Liquid crystalline medium
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
JP5798066B2 (ja) 2012-03-08 2015-10-21 富士フイルム株式会社 化合物、液晶組成物、高分子材料およびフィルム
JP5804991B2 (ja) 2012-03-19 2015-11-04 富士フイルム株式会社 光反射フィルム、自動車用フロントガラス、建材用ガラス
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
SG11201406889WA (en) 2012-05-30 2015-02-27 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides
JP5867298B2 (ja) 2012-06-06 2016-02-24 Jsr株式会社 フォトレジスト組成物及びレジストパターン形成方法
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
WO2014005125A2 (en) 2012-06-29 2014-01-03 Biotium, Inc. Fluorescent compounds and uses thereof
US9040498B2 (en) 2012-07-06 2015-05-26 Research Foundation Of The City University Of New York 1,2,3-Triazolyl purine derivatives
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
AU2013291098A1 (en) 2012-07-19 2015-02-05 Sumitomo Dainippon Pharma Co., Ltd. 1-(cycloalkyl-carbonyl)proline derivative
NZ703851A (en) 2012-07-27 2017-01-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014020152A1 (en) 2012-08-02 2014-02-06 Graffinity Pharmaceuticals Gmbh Ligands for apheresis and immunoabsorption
EP2892899B1 (en) 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CA2885217C (en) 2012-09-20 2019-10-08 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
FR2997851B1 (fr) 2012-11-09 2014-11-28 Oreal Composition comprenant un derive dicarbonyle et procede de lissage des cheveux a partir de cette composition
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
CN104918940B (zh) 2012-11-16 2017-03-08 默沙东公司 人磷脂酰肌醇3‑激酶δ的嘌呤抑制剂
CN104903307A (zh) 2012-12-06 2015-09-09 默沙东公司 二硫化物屏蔽的前体药物组合物和方法
MX2015008288A (es) 2013-01-08 2016-06-02 Savira Pharmaceuticals Gmbh Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SI2951172T1 (sl) 2013-01-29 2017-08-31 Redx Pharma Plc Piridin derivati kot inhibitorji mehkih kamnov
NZ710111A (en) 2013-01-31 2020-08-28 Vertex Pharma Quinoline and quinoxaline amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
SMT201700256T1 (it) 2013-01-31 2017-09-07 Vertex Pharma Piridone ammidi come modulatori di canali del sodio
CA2898653C (en) * 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
JP2014232188A (ja) 2013-05-29 2014-12-11 コニカミノルタ株式会社 セルロースアシレートフィルム、円偏光板及び画像表示装置
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
EP3019615B1 (en) 2013-07-12 2021-04-07 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
WO2015003723A1 (en) 2013-07-12 2015-01-15 Københavns Universitet Substituted 4-proline derivatives as iglur antagonists
WO2015003991A1 (en) 2013-07-12 2015-01-15 Syngenta Participations Ag Novel microbiocides
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
WO2015011284A2 (en) 2013-07-25 2015-01-29 Fondazione Telethon Inhibitors of fapp2 and uses thereof
EP3041470A4 (en) 2013-09-04 2017-05-03 Board Of Regents Of the University Of Texas System Methods and compositions for selective and targeted cancer therapy
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
EP3052483B1 (en) 2013-10-01 2019-02-06 GlaxoSmithKline Intellectual Property Development Limited Compounds for affinity chromatography
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
WO2015054337A1 (en) 2013-10-09 2015-04-16 Emory University Heterocyclic coupling catalysts and methods related thereto
HUE049827T2 (hu) 2013-12-03 2020-10-28 Fmc Corp Pirrolidinonok mint herbicidek
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10131841B2 (en) 2013-12-16 2018-11-20 Merck Patent Gmbh Liquid-crystalline medium
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2015103317A1 (en) 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
AU2015243437B2 (en) 2014-04-09 2019-08-29 Siteone Therapeutics, Inc. 10',11'-modified saxitoxins useful for the treatment of pain
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
JP6295992B2 (ja) 2014-05-09 2018-03-20 信越化学工業株式会社 単量体の製造方法
US9701627B2 (en) 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016007837A1 (en) 2014-07-11 2016-01-14 Spero Therapeutics, Inc. Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors
MX381342B (es) 2014-07-16 2025-03-12 Lifesci Pharmaceuticals Inc Compuestos terapeuticos inhibidores.
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2017002985A (es) 2014-09-10 2017-11-17 Epizyme Inc Inhibidores de smyd.
US9783527B2 (en) 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
JP2016079098A (ja) 2014-10-10 2016-05-16 塩野義製薬株式会社 セフェム化合物
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
EP4403042A3 (en) 2014-12-10 2025-03-05 Mars, Incorporated Flavor compositions and pet food products containing the same
FR3030242B1 (fr) 2014-12-18 2018-01-26 L'oreal Emulsion contenant un tensioactif gemine ayant deux groupements amide gras et un filtre uv organique hydrosoluble
CN105985330A (zh) 2015-02-04 2016-10-05 苏州旺山旺水生物医药有限公司 一类杂环化合物、其制备方法和用途
JP6394430B2 (ja) 2015-02-13 2018-09-26 信越化学工業株式会社 化合物、高分子化合物、レジスト材料及びパターン形成方法
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
EP3085360A1 (en) 2015-04-20 2016-10-26 Universite De Bordeaux Lipid based nanocarrier compositions loaded with metal nanoparticles and therapeutic agent
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
EP3294732B1 (en) 2015-05-15 2019-09-25 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
RU2017142979A (ru) 2015-06-02 2019-07-15 ЭфЭмСи Корпорейшн Замещенные циклические амиды и их применение в качестве гербицидов
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
PE20181173A1 (es) 2015-07-06 2018-07-20 Bayer Cropscience Ag Heterociclos nitrogenados como pesticidas
JP2018526430A (ja) 2015-07-10 2018-09-13 アルヴィナス・インコーポレイテッド タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法
CN106518767A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
CN106518766A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 新型二芳基脲类化合物,其制备方法及其医药用途
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
EP3356370B1 (en) 2015-09-30 2021-08-18 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2017059446A1 (en) 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
WO2017062751A1 (en) 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
CA3001857A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
ES2914225T3 (es) 2015-10-16 2022-06-08 Modernatx Inc Análogos de cap de ARNm con enlace de fosfato modificado
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
ES2869229T3 (es) 2015-11-27 2021-10-25 Mitsubishi Tanabe Pharma Corp Derivados de 2-(((pirrolidin-3-il)carbonil)amino)-1H-imidazol como agonistas del receptor de melanocortina 1 (MCR1) para tratar la artritis reumatoide
GB201522232D0 (en) 2015-12-16 2016-01-27 Liverpool School Tropical Medicine Combination product
KR102606339B1 (ko) 2016-03-02 2023-11-24 삼성전자주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN105906591A (zh) 2016-04-22 2016-08-31 中国药科大学 2-氨基-γ-丁内酯类盐酸盐的合成
TWI844006B (zh) * 2016-05-05 2024-06-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2017223260A1 (en) 2016-06-23 2017-12-28 Albert Einstein College Of Medicine, Inc. Pu.1 inhibitors
CN106220667B (zh) 2016-07-21 2018-10-30 北京航空航天大学 螺环有机硅化合物及其应用
WO2018045106A1 (en) 2016-08-30 2018-03-08 Ohio State Innovation Foundation Anti-fungal treatment
WO2018055235A1 (en) 2016-09-21 2018-03-29 University Of Helsinki Isoxazole-amides for treating cardiac diseases
US11820932B2 (en) 2016-09-28 2023-11-21 Merck Patent Gmbh Polymerisable liquid crystal material and polymerised liquid crystal film
KR20190063473A (ko) 2016-09-28 2019-06-07 블레이드 테라퓨틱스, 인크. 칼페인 조정자 및 그 치료학적 용도
US11179708B2 (en) 2016-10-04 2021-11-23 Massachusetts Institute Of Technology Compositions and methods for selective carbonylation of heterocyclic compounds
US11142535B2 (en) 2016-12-12 2021-10-12 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2018163077A1 (en) * 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
KR20200012833A (ko) 2017-03-29 2020-02-05 사이트원 테라퓨틱스, 인코포레이티드 통증 치료용 11,13-개질된 색시톡신
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3601058B1 (en) 2017-03-30 2025-06-18 Shaw Industries Group, Inc. Carpet tiles and systems and methods of making same
WO2018183923A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Methods of using ehmt2 inhibitors
JP2020100564A (ja) 2017-04-03 2020-07-02 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
CN110785414A (zh) 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras调节剂
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
BR112019024016A2 (pt) 2017-05-16 2020-06-09 Vertex Pharma amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
CN107033149B (zh) 2017-06-12 2020-01-03 上海交通大学 一种dpp-4酶抑制剂及其制备和应用
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN109320509B (zh) 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
CN109384712B (zh) 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
MX2020001793A (es) 2017-08-17 2020-07-22 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
US11795162B2 (en) 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
US20210260040A1 (en) 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders
JP2021500327A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法
EP3700527A4 (en) 2017-10-25 2021-03-10 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHOD OF USING THEM
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
WO2019094732A1 (en) 2017-11-10 2019-05-16 Academia Sinica Inhibitors of cyclic-amp response element-binding protein
WO2019097515A1 (en) 2017-11-15 2019-05-23 Metabomed Ltd Acss2 inhibitors and methods of use thereof
EP3502684A1 (en) 2017-12-22 2019-06-26 Universite De Bordeaux Method for metal ion detection in aqueous solutions using nucleolipid compounds
KR20190076339A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
WO2019137201A1 (zh) 2018-01-09 2019-07-18 四川科伦博泰生物医药股份有限公司 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
AU2019219123B2 (en) 2018-02-08 2022-12-08 Enyo Pharma Non-fused thiophene derivatives and their uses
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
US12575877B2 (en) 2018-04-05 2026-03-17 St. Jude Medical, Cardiology Division, Inc. High density electrode mapping catheter
KR102785469B1 (ko) 2018-04-27 2025-03-26 메르크 파텐트 게엠베하 중합성 액정 물질 및 중합된 액정 필름
EP3784754B1 (en) 2018-04-27 2022-06-08 Merck Patent GmbH Polymerisable liquid crystal material and polymerised liquid crystal film
TWI902662B (zh) 2018-05-16 2025-11-01 仁新醫藥股份有限公司 脂肪酸類似物及使用方法
TWI812739B (zh) 2018-06-21 2023-08-21 景凱生物科技股份有限公司 Nadph氧化酶抑制劑、含其的醫藥組合物、及其應用
CA3105748A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
EP3831823A4 (en) 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
WO2020034062A1 (en) 2018-08-13 2020-02-20 Rhodia Operations Process for the reductive amination of a carbonyl compound
WO2020034058A1 (en) 2018-08-13 2020-02-20 Rhodia Operations PROCESS FOR REDUCTIVE AMINATION OF α,β-UNSATURATED CARBONYL COMPOUND
WO2020051207A2 (en) 2018-09-04 2020-03-12 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and methods of use
CN113164454A (zh) 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
KR102092838B1 (ko) 2018-10-02 2020-03-24 성균관대학교산학협력단 신규 퓨란계 폴리카보네이트 및 이의 제조 방법
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
TW202028183A (zh) 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
AU2019362788A1 (en) 2018-10-15 2021-04-15 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
KR102151855B1 (ko) 2018-11-30 2020-09-03 롯데케미칼 주식회사 공액 디엔계 및 방향족 비닐계 공중합체의 제조 방법 및 이로부터 제조된 공액 디엔계 및 방향족 비닐계의 공중합체를 포함하는 타이어
US12377079B2 (en) 2018-12-06 2025-08-05 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
EP3894392A4 (en) 2018-12-11 2022-08-24 Duke University COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
EP3914669B1 (en) 2019-01-22 2024-10-02 Merck Patent GmbH Method for the preparation of a liquid crystal polymer film
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
US20220160705A1 (en) 2019-03-20 2022-05-26 Cornell University Methods for controlling prostaglandin-mediated biological processes
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
US12162834B2 (en) 2019-04-30 2024-12-10 Merck Patent Gmbh Reactive mesogens
KR20220007681A (ko) 2019-05-10 2022-01-18 와커 헤미 아게 양이온성 게르마늄(ii) 화합물, 그의 제조 방법, 및 히드로실릴화에서의 촉매로서의 그의 용도
EP3983386A4 (en) 2019-05-14 2023-01-11 Metabomed Ltd ACSS2 INHIBITORS AND METHODS OF USE THEREOF
US20220324880A1 (en) 2019-06-10 2022-10-13 Kymara Therapeutics, Inc. Smarca inhibitors and uses thereof
EP3986888A1 (en) 2019-06-21 2022-04-27 Bayer Aktiengesellschaft Thienylhydroxyisoxazolines and derivatives thereof
WO2021001739A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translational enhancers and related methods
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
US20240156778A1 (en) 2019-10-17 2024-05-16 Enyo Pharma Thiophene derivatives for use in treating portal inflammation and fibrosis
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
WO2021125797A1 (ko) 2019-12-20 2021-06-24 주식회사 삼양홀딩스 올라파립의 용해도 및 생체이용율이 개선된 조성물
WO2021239117A1 (en) 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
EP4217442B1 (en) 2020-09-24 2025-06-18 Merck Patent GmbH Polymerizable liquid crystal material and polymerized liquid crystal film
WO2022070048A1 (en) 2020-09-29 2022-04-07 Cadila Healthcare Limited Novel amide derivatives
US20230405008A1 (en) 2020-10-21 2023-12-21 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques

Also Published As

Publication number Publication date
CO2022008969A2 (es) 2022-09-09
CR20220316A (es) 2022-10-07
FI4069691T3 (fi) 2024-11-13
TW202128675A (zh) 2021-08-01
JP2023504546A (ja) 2023-02-03
CL2022001489A1 (es) 2023-03-03
KR20220124176A (ko) 2022-09-13
MX2022006865A (es) 2022-07-11
US20210198241A1 (en) 2021-07-01
CN114945566B (zh) 2024-11-12
RS66307B1 (sr) 2025-01-31
CA3164134A1 (en) 2021-06-10
DOP2025000288A (es) 2025-12-30
EP4069691B1 (en) 2024-09-18
EP4506001A2 (en) 2025-02-12
MD4069691T2 (ro) 2025-03-31
US20230286961A1 (en) 2023-09-14
MA57825B1 (fr) 2024-11-29
EP4069691A1 (en) 2022-10-12
UA130303C2 (uk) 2026-01-14
LT4069691T (lt) 2024-12-10
JP7664925B2 (ja) 2025-04-18
DK4069691T3 (da) 2024-10-28
JP2025111504A (ja) 2025-07-30
JOP20220130B1 (ar) 2025-10-01
WO2021113627A1 (en) 2021-06-10
SMT202400488T1 (it) 2025-01-14
US11834441B2 (en) 2023-12-05
AU2020397059A1 (en) 2022-07-21
JOP20220130A1 (ar) 2023-01-30
US11919887B2 (en) 2024-03-05
CN114945566A (zh) 2022-08-26
UY38979A (es) 2021-07-30
PL4069691T3 (pl) 2025-01-27
EP4506001A3 (en) 2025-04-30
US20240391907A1 (en) 2024-11-28
IL293592A (en) 2022-08-01
PE20230300A1 (es) 2023-02-13
US12247021B2 (en) 2025-03-11
HRP20241695T1 (hr) 2025-02-14
HUE069128T2 (hu) 2025-02-28
US20250197381A1 (en) 2025-06-19
DOP2022000115A (es) 2022-09-30
AR120680A1 (es) 2022-03-09
PT4069691T (pt) 2024-12-18
TWI891687B (zh) 2025-08-01
ES2998396T3 (en) 2025-02-20
BR112022010924A2 (pt) 2022-09-06
PH12022551379A1 (en) 2023-05-03
SI4069691T1 (sl) 2025-02-28

Similar Documents

Publication Publication Date Title
ECSP22052564A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
UY39800A (es) N–(hidroxialquil (hetero)aril) tetrahidrofuran carboxamidas como moduladores de canales de sodio
CO2019013021A2 (es) Amidas de piridona deuteradas y sus profármacos como moduladores de los canales de sodio
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
CL2021002144A1 (es) Compuesto heterociclo pentacíclico.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов